The use of adalimumab in the management of Crohn's disease: Scottish society of gastroenterology audit 2007

被引：0
|
作者：
Ho, G.
Smith, L.
Aitken, S.
Lee, H.
Ting, D.
Fennell, J.
Lees, C.
Palmer, K.
Penman, I.
Shand, A.
Arnott, I.
Priest, M.
Boulton-Jones, R. [1 ]
Russell, R.
Mowat, C. [2 ]
Wilson, D. [3 ]
Satsangi, J.
机构：
[1] Yorkhill Hosp, Gastrointestinal Unit, Glasgow, Lanark, Scotland
[2] Ninewells Hosp, Gastrointestinal Unit, Dundee, Scotland
[3] Royal Hosp Sick Childrens, Gastrointestinal Unit, Dundee, Scotland
来源：
GUT | 2008年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
001
引用
收藏
页码：A1 / A1
页数：1
相关论文
共 50 条
  • [11] Effectiveness and safety of infliximab and adalimumab for ambulatory Crohn's disease patients in primary gastroenterology centres
    Tursi, Antonio
    Elisei, Walter
    Picchio, Marcello
    Penna, Antonio
    Lecca, Piera Giuseppina
    Forti, Giacomo
    Giorgetti, GianMarco
    Faggiani, Roberto
    Zampaletta, Costantino
    Pelecca, Giorgio
    Brandimarte, Giovanni
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2014, 25 (05) : 485 - 490
  • [12] Adalimumab for the treatment of Crohn's disease - Consensus Paper of the Working Group "Chronic Inflammatory Bowel Diseases" of the Austrian Society for Gastroenterology and Hepatology
    Reinisch, W.
    Haas, T.
    Kaser, A.
    Petritsch, W.
    Vogelsang, H.
    Feichtenschlager, T.
    Novacek, G.
    Siebert, F.
    Tilg, H.
    Knoflach, R.
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2009, 47 (04): : 372 - 380
  • [13] Adalimumab for the treatment of Crohn's disease
    Cassinotti, Andrea
    Ardizzone, Sandro
    Porro, Gabriele Bianchi
    BIOLOGICS-TARGETS & THERAPY, 2008, 2 (04): : 763 - 777
  • [14] Adalimumab for the treatment of Crohn's disease
    Devlin, Shane M.
    Panaccione, Remo
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2008, 8 (07) : 1011 - 1019
  • [15] Pharmacokinetics of adalimumab in Crohn’s disease
    David Ternant
    Konstantinos Karmiris
    Severine Vermeire
    Céline Desvignes
    Nicolas Azzopardi
    Theodora Bejan-Angoulvant
    Gert van Assche
    Gilles Paintaud
    European Journal of Clinical Pharmacology, 2015, 71 : 1155 - 1157
  • [16] Adalimumab induction for Crohn's disease
    Cottone, M
    Mocciaro, F
    Scimeca, D
    GASTROENTEROLOGY, 2006, 130 (06) : 1929 - 1929
  • [17] Letter: infliximab and adalimumab in the management of Crohn's disease - are they really comparable?
    Lopez-Sanroman, A.
    Gisbert, J. P.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2012, 36 (05) : 498 - 499
  • [18] Adalimumab in pediatric Crohn's disease
    Patel, Ashish S.
    Suarez, Lisbet D.
    Rosh, Joel R.
    IMMUNOTHERAPY, 2016, 8 (02) : 127 - 133
  • [19] Pharmacokinetics of adalimumab in Crohn's disease
    Ternant, David
    Karmiris, Konstantinos
    Vermeire, Severine
    Desvignes, Celine
    Azzopardi, Nicolas
    Bejan-Angoulvant, Theodora
    van Assche, Gert
    Paintaud, Gilles
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 71 (09) : 1155 - 1157
  • [20] Use of Adalimumab in Crohn's Related Cavitary and Granulomatous Lung Disease
    Barish, Charles
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2009, 104 : S361 - S361
12345